WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > Targovax ASA
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
MedTech, Industrial Impact
Atreca, Inc. | February 07, 2023
On February 6, 2023, Atreca, Inc. (Atreca), a biotechnology company that develops novel therapeutics through a deep understanding of the human immune response, with a focus on innovative novel cancer immunotherapeutics, and Xencor, Inc., a clinical-stage biopharmaceutical company that develops cytokines and engineered antibodies for the treatment of autoimmune diseases and cancer, announced, as part of their existing strategic collaboration, that they have mutually selected the first progr...
Diagnostics
VeriSIM Life | May 30, 2022
VeriSIM Life (VeriSIM), the leading artificial intelligence (AI)-enabled, unique R&D decisions de-risker for breakthrough drug development, today announced that it has entered into a partnership agreement with Total Brain www.totalbrain.com, an applied, integrative neuroscience company, to create breakthrough neurodata-driven actionable insights for developing novel drugs to treat a wide range of neurological disorders. The partnership will pioneer the integration of Total Bra...
Industrial Impact
c-LEcta | February 16, 2022
c-LEcta, a leading biotechnology company in enzyme engineering and bioprocess development, has announced that it has reached an agreement with Kerry Group for it to acquire a majority shareholding of the company. Kerry is a world-leading taste and nutrition partner for the food, beverage, and pharmaceutical markets. This strategically compelling combination will accelerate Kerry’s innovation capabilities in enzyme engineering, fermentation and bio-process development while also enabling c-...
Cell and Gene Therapy
NeuExcell Therapeutics | September 13, 2021
NeuExcell Therapeutics and Spark Therapeutics, a member of the Roche Group announced a gene therapy collaboration aimed at developing a safe and effective treatment for patients suffering from Huntington's Disease (HD). Under the terms of the agreement, Spark Therapeutics will receive access to NeuExcell's proprietary neuro-regenerative gene therapy platform and capabilities. NeuExcell's research team will collaborate closely with Spark Therapeutics to advance the prog...
Medical, Industry Outlook
Whitepaper
MedTech
Video
Cell and Gene Therapy, Medical
Medical
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE